BR112015012512A2 - trans-4-{2-[4-(2,3-diclorofenil)-piperazina-1-il]-etil}-n,n-dimetilcarbamoil-ciclo-hexilamina para o tratamento de sintomas negativos da esquizofrenia - Google Patents

trans-4-{2-[4-(2,3-diclorofenil)-piperazina-1-il]-etil}-n,n-dimetilcarbamoil-ciclo-hexilamina para o tratamento de sintomas negativos da esquizofrenia

Info

Publication number
BR112015012512A2
BR112015012512A2 BR112015012512A BR112015012512A BR112015012512A2 BR 112015012512 A2 BR112015012512 A2 BR 112015012512A2 BR 112015012512 A BR112015012512 A BR 112015012512A BR 112015012512 A BR112015012512 A BR 112015012512A BR 112015012512 A2 BR112015012512 A2 BR 112015012512A2
Authority
BR
Brazil
Prior art keywords
schizophrenia
dimethylcarbamoyl
cyclohexylamine
dichlorophenyl
trans
Prior art date
Application number
BR112015012512A
Other languages
English (en)
Inventor
Szatmári Balázs
József Németh György
Laszlovszky István
György Pitter János
Debelle Marc
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of BR112015012512A2 publication Critical patent/BR112015012512A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo “trans-4-{2-[4-(2,3-diclorofenil)-piperazina-1-il]-etil}-n,n-dimetilcarbamoil-ciclo-hexilamina para o tratamento de sintomas negativos da esquizofrenia” a presente invenção refere-se à trans-4-{2-[4-(2,3-diclorofenil)piperazin-1-il]-etil}-n,n-dimetilcarbamoil-ciclo-hexilamina (cariprazina) e seus sais farmaceuticamente aceitáveis e hidratos e solvatos e polimorfos da mesma para uso no tratamento de sintomas negativos primários da esquizofrenia e/ou sintomas predominantemente negativos de esquizofrenia.
BR112015012512A 2012-11-29 2013-11-28 trans-4-{2-[4-(2,3-diclorofenil)-piperazina-1-il]-etil}-n,n-dimetilcarbamoil-ciclo-hexilamina para o tratamento de sintomas negativos da esquizofrenia BR112015012512A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1200691A HU231227B1 (hu) 2012-11-29 2012-11-29 Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
PCT/IB2013/060465 WO2014083522A1 (en) 2012-11-29 2013-11-28 Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating negative symptoms of schizophrenia

Publications (1)

Publication Number Publication Date
BR112015012512A2 true BR112015012512A2 (pt) 2017-07-11

Family

ID=70289034

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012512A BR112015012512A2 (pt) 2012-11-29 2013-11-28 trans-4-{2-[4-(2,3-diclorofenil)-piperazina-1-il]-etil}-n,n-dimetilcarbamoil-ciclo-hexilamina para o tratamento de sintomas negativos da esquizofrenia

Country Status (36)

Country Link
US (1) US20150306094A1 (pt)
EP (2) EP2925324B1 (pt)
JP (2) JP2016501215A (pt)
KR (2) KR20210010955A (pt)
CN (1) CN104812390A (pt)
AP (1) AP2015008448A0 (pt)
AU (1) AU2013350819B9 (pt)
BR (1) BR112015012512A2 (pt)
CA (1) CA2890952A1 (pt)
CL (1) CL2015001468A1 (pt)
CR (1) CR20150244A (pt)
CY (1) CY1123766T1 (pt)
DK (1) DK2925324T3 (pt)
EA (1) EA039245B1 (pt)
ES (1) ES2863052T3 (pt)
GE (1) GEP20186849B (pt)
HK (1) HK1212608A1 (pt)
HR (1) HRP20210486T1 (pt)
HU (2) HU231227B1 (pt)
IL (1) IL238723B (pt)
LT (1) LT2925324T (pt)
MD (2) MD4865C1 (pt)
MX (2) MX2015006677A (pt)
MY (1) MY174663A (pt)
NI (1) NI201500074A (pt)
NZ (1) NZ708295A (pt)
PE (1) PE20151052A1 (pt)
PH (1) PH12015501124A1 (pt)
PL (1) PL2925324T3 (pt)
PT (1) PT2925324T (pt)
RS (1) RS61509B1 (pt)
SG (1) SG11201503672SA (pt)
SI (1) SI2925324T1 (pt)
UA (1) UA123492C2 (pt)
WO (1) WO2014083522A1 (pt)
ZA (1) ZA201503660B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2317852T3 (en) 2008-07-16 2015-03-23 Richter Gedeon Nyrt PHARMACEUTICAL FORMULATIONS CONTAINING dopamine receptor ligands
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231173B1 (hu) * 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Ipari eljárás cariprazine előállítására
WO2019016828A1 (en) * 2017-07-15 2019-01-24 Msn Laboratories Private Limited, R&D Center NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N- {4- [2- [4- (2,3-DICHLOROPHENYL) PIPERAZIN-1-YL] ETHYL] CYCLOHEXYL} -N ', N'-DIMETHYLUMED HYDROCHLORIDE AND POLYMORPHS THIS ONE
US20200375983A1 (en) * 2017-12-01 2020-12-03 Aurobindo Pharma Ltd A process for the preparation of cariprazine hydrochloride
WO2020056929A1 (zh) * 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11344503B2 (en) 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HU230748B1 (hu) 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
HUP0700369A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
KR20100022955A (ko) * 2007-05-24 2010-03-03 리히터 게데온 닐트. (티오) -카르바모일-시클로헥산 유도체 및 정신분열 치료 방법
WO2010126527A1 (en) * 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders

Also Published As

Publication number Publication date
LT2925324T (lt) 2021-02-25
SI2925324T1 (sl) 2021-04-30
IL238723A0 (en) 2015-06-30
MX2021000342A (es) 2021-04-13
PH12015501124B1 (en) 2015-08-03
WO2014083522A1 (en) 2014-06-05
IL238723B (en) 2020-02-27
SG11201503672SA (en) 2015-06-29
EP2925324A1 (en) 2015-10-07
CY1123766T1 (el) 2022-05-27
UA123492C2 (uk) 2021-04-14
AU2013350819B2 (en) 2018-05-31
KR20210010955A (ko) 2021-01-28
HUP1200691A1 (pt) 2014-06-30
PT2925324T (pt) 2021-02-16
CR20150244A (es) 2015-06-23
PH12015501124A1 (en) 2015-08-03
EP3653211A1 (en) 2020-05-20
HUE054054T2 (hu) 2021-08-30
HRP20210486T1 (hr) 2021-05-14
JP2016501215A (ja) 2016-01-18
MD20200089A2 (ro) 2021-05-31
EP2925324B1 (en) 2020-12-30
MD4865C1 (ro) 2024-02-29
RS61509B1 (sr) 2021-03-31
CL2015001468A1 (es) 2015-08-07
AP2015008448A0 (en) 2015-05-31
HU231227B1 (hu) 2022-03-28
KR102314248B1 (ko) 2021-10-19
PE20151052A1 (es) 2015-08-09
EA039245B1 (ru) 2021-12-22
PL2925324T3 (pl) 2021-06-28
CN104812390A (zh) 2015-07-29
NI201500074A (es) 2015-09-18
JP2019163240A (ja) 2019-09-26
KR20150088270A (ko) 2015-07-31
AU2013350819B9 (en) 2018-06-21
MD4865B1 (ro) 2023-07-31
MX2015006677A (es) 2015-08-10
CA2890952A1 (en) 2014-06-05
GEP20186849B (en) 2018-05-10
DK2925324T3 (da) 2021-03-01
US20150306094A1 (en) 2015-10-29
ZA201503660B (en) 2016-03-30
AU2013350819A1 (en) 2015-06-04
HK1212608A1 (zh) 2016-06-17
MD20150058A2 (ro) 2015-11-30
EA201500575A1 (ru) 2015-09-30
MY174663A (en) 2020-05-05
NZ708295A (en) 2020-03-27
ES2863052T3 (es) 2021-10-08

Similar Documents

Publication Publication Date Title
BR112015012512A2 (pt) trans-4-{2-[4-(2,3-diclorofenil)-piperazina-1-il]-etil}-n,n-dimetilcarbamoil-ciclo-hexilamina para o tratamento de sintomas negativos da esquizofrenia
CY1119076T1 (el) Αλατα πιπεραζινης ως ανταγωνιστες των d3/d2
CY1122046T1 (el) Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων
ECSP099819A (es) Metabolitos de derivados del (tio)-carbamoil-ciclohexano
GEP20135730B (en) Trans-4-{2-[4-(2,3-dichlorophe-nyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treatment of schizophrenia
GEP20135731B (en) Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethyl carbamoyl-cyclohexylamine for acute mania treatment
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
TR201906532T4 (tr) Kinin bileşikleri ve optik izomerleri, hazırlanış yöntemleri ve tıbbi kullanımları.
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
BR112019008415A2 (pt) composto de piridona e inibidor de c-met, composição farmacêutica e uso dos mesmos
CL2012001641A1 (es) Compuestos derivados de piperazina; composición farmacéutica; que comprende a uno de los compuestos y uso de los compuestos en la preparación de medicamentos para el tratamiento y/o prevención de infecciones por protozoos, en forma particular para el tratamiento y/o prevención de la malaria.
BR112022005723A2 (pt) Compostos de indol carboxamida e seu uso para o tratamento de infecções micobacterianas
BR112017020917A2 (pt) derivados de ácido biliar como agonistas de fxr/tgr5 e seus métodos de uso
CU20090190A7 (es) Sales novedosas de piperazina como antagonistas d3/d2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]